KR100907938B1 - 발기 기능장애의 치료를 위한 알카노일 l-카르니틴의 용도 - Google Patents
발기 기능장애의 치료를 위한 알카노일 l-카르니틴의 용도 Download PDFInfo
- Publication number
- KR100907938B1 KR100907938B1 KR1020047007882A KR20047007882A KR100907938B1 KR 100907938 B1 KR100907938 B1 KR 100907938B1 KR 1020047007882 A KR1020047007882 A KR 1020047007882A KR 20047007882 A KR20047007882 A KR 20047007882A KR 100907938 B1 KR100907938 B1 KR 100907938B1
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- erectile dysfunction
- carnitine
- treatment
- alkanoyl
- Prior art date
Links
- 208000010228 Erectile Dysfunction Diseases 0.000 title claims abstract description 34
- 201000001881 impotence Diseases 0.000 title claims abstract description 34
- -1 alkanoyl L-carnitine Chemical compound 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims description 20
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 9
- 229960003310 sildenafil Drugs 0.000 claims description 9
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 claims description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 229940095064 tartrate Drugs 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-M 2-aminoethanesulfonate Chemical compound NCCS([O-])(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-M 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims description 2
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 229940009098 aspartate Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229960005336 magnesium citrate Drugs 0.000 claims description 2
- 235000002538 magnesium citrate Nutrition 0.000 claims description 2
- 239000004337 magnesium citrate Substances 0.000 claims description 2
- 229940091250 magnesium supplement Drugs 0.000 claims description 2
- 229940095060 magnesium tartrate Drugs 0.000 claims description 2
- MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 claims description 2
- QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 claims description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229940066528 trichloroacetate Drugs 0.000 claims description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 2
- 150000001805 chlorine compounds Chemical group 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 18
- 210000002460 smooth muscle Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 5
- 150000003180 prostaglandins Chemical class 0.000 description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229960004046 apomorphine Drugs 0.000 description 3
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003899 penis Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 229960000711 alprostadil Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 2
- 238000009552 doppler ultrasonography Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229960001789 papaverine Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 229940103090 sildenafil 50 mg Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- LRCNOZRCYBNMEP-SECBINFHSA-N O-isobutyryl-L-carnitine Chemical group CC(C)C(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C LRCNOZRCYBNMEP-SECBINFHSA-N 0.000 description 1
- 206010052004 Organic erectile dysfunction Diseases 0.000 description 1
- 206010034319 Penile swelling Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008555 neuronal activation Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000001129 nonadrenergic effect Effects 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
Claims (13)
- 프로피오닐 L-카르니틴 또는 그의 약학적으로 허용 가능한 염과 실데나필을 유효성분으로 포함하는 발기 기능장애 치료용 약학조성물.
- 삭제
- 제 1 항에 있어서, 약학적으로 허용 가능한 염이 클로라이드, 브로마이드, 오로테이트, 산 아스파테이트, 산 시트레이트, 마그네슘 시트레이트, 산 포스페이트, 푸마레이트 및 산 푸마레이트, 마그네슘 푸마레이트, 락테이트, 말리에이트, 산 말리에이트, 뮤케이트, 산 옥살레이트, 파모에이트, 산 파모에이트, 산 설페이트, 글루코스 포스페이트, 타르트레이트, 산 타르트레이트, 마그네슘 타르트레이트, 2-아미노 에탄설포네이트, 마그네슘 2-아미노 에탄설포네이트, 콜린 타르트레이트 및 트리클로로아세테이트로 이루어진 그룹 중에서 선택되는 것을 특징으로 하는 약학조성물.
- 삭제
- 삭제
- 제 1 항에 있어서, 약학적으로 허용 가능한 하나 이상의 부형제 또는 희석제를 포함하는 것을 특징으로 하는 약학조성물.
- 제 1 항에 있어서, 발기 기능장애 치료용 약제의 제조에 사용되는 것을 특징으로 하는 약학조성물.
- 제 1 항에 있어서, 당뇨병에 걸린 환자의 발기 기능장애 치료용 약제의 제조에 사용되는 것을 특징으로 하는 약학조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITRM2001A000708 | 2001-12-04 | ||
IT2001RM000708A ITRM20010708A1 (it) | 2001-12-04 | 2001-12-04 | Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile. |
PCT/IT2002/000758 WO2003047563A1 (en) | 2001-12-04 | 2002-12-04 | Use of alkanoyl l-carnitine for the treatment of erectile dysfunction |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050044594A KR20050044594A (ko) | 2005-05-12 |
KR100907938B1 true KR100907938B1 (ko) | 2009-07-16 |
Family
ID=11455907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020047007882A KR100907938B1 (ko) | 2001-12-04 | 2002-12-04 | 발기 기능장애의 치료를 위한 알카노일 l-카르니틴의 용도 |
Country Status (16)
Country | Link |
---|---|
US (3) | US20050080018A1 (ko) |
EP (1) | EP1450782B9 (ko) |
JP (1) | JP4370169B2 (ko) |
KR (1) | KR100907938B1 (ko) |
AT (1) | ATE309800T1 (ko) |
AU (1) | AU2002365847A1 (ko) |
CA (1) | CA2465471C (ko) |
DE (1) | DE60207442T2 (ko) |
DK (1) | DK1450782T3 (ko) |
ES (1) | ES2250749T3 (ko) |
HU (1) | HU229214B1 (ko) |
IT (1) | ITRM20010708A1 (ko) |
MX (1) | MXPA04005269A (ko) |
PL (1) | PL211211B1 (ko) |
SI (1) | SI1450782T1 (ko) |
WO (1) | WO2003047563A1 (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20040561A1 (it) * | 2004-11-11 | 2005-02-11 | Sigma Tau Ind Farmaceuti | Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile. |
IT1397867B1 (it) * | 2010-02-03 | 2013-02-04 | Brotzu | Liposomi contenenti prostaglandina e1 (pge1), formulazioni che li contengono e loro uso |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
HUE041709T2 (hu) | 2013-04-05 | 2019-05-28 | Boehringer Ingelheim Int | Az empagliflozin terápiás alkalmazásai |
PL2986304T3 (pl) | 2013-04-18 | 2022-05-02 | Boehringer Ingelheim International Gmbh | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania |
US20180104268A1 (en) * | 2015-04-30 | 2018-04-19 | Boehringer Ingelheim International Gmbh | Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999003364A1 (en) * | 1997-07-16 | 1999-01-28 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Nutritional composition for subjects under stress |
WO2001026666A2 (en) * | 1999-10-08 | 2001-04-19 | Sigma-Tau Healthscience S.P.A. | Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2903579A1 (de) * | 1978-02-03 | 1979-08-09 | Sigma Tau Ind Farmaceuti | Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel |
ATE187329T1 (de) * | 1996-03-04 | 1999-12-15 | Sigma Tau Ind Farmaceuti | Carnitinderivat als arzneimittel zur behandlung von arteriosklerose obliterans |
IT1290801B1 (it) * | 1996-07-05 | 1998-12-11 | Mendes Srl | Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili |
US6133281A (en) * | 1996-10-24 | 2000-10-17 | Harbor-Ucla Research And Education Institute | NMDA receptor blockers in the therapy of urogenital disease |
US20020119933A1 (en) * | 2000-07-28 | 2002-08-29 | Butler Terri L. | Compositions and methods for improving cardiovascular function |
US6241471B1 (en) * | 1999-08-26 | 2001-06-05 | General Electric Co. | Turbine bucket tip shroud reinforcement |
-
2001
- 2001-12-04 IT IT2001RM000708A patent/ITRM20010708A1/it unknown
-
2002
- 2002-12-04 US US10/497,498 patent/US20050080018A1/en not_active Abandoned
- 2002-12-04 ES ES02804338T patent/ES2250749T3/es not_active Expired - Lifetime
- 2002-12-04 DE DE60207442T patent/DE60207442T2/de not_active Expired - Lifetime
- 2002-12-04 AU AU2002365847A patent/AU2002365847A1/en not_active Abandoned
- 2002-12-04 CA CA2465471A patent/CA2465471C/en not_active Expired - Fee Related
- 2002-12-04 EP EP02804338A patent/EP1450782B9/en not_active Expired - Lifetime
- 2002-12-04 HU HU0402062A patent/HU229214B1/hu not_active IP Right Cessation
- 2002-12-04 WO PCT/IT2002/000758 patent/WO2003047563A1/en active IP Right Grant
- 2002-12-04 KR KR1020047007882A patent/KR100907938B1/ko active IP Right Grant
- 2002-12-04 SI SI200230234T patent/SI1450782T1/sl unknown
- 2002-12-04 MX MXPA04005269A patent/MXPA04005269A/es active IP Right Grant
- 2002-12-04 DK DK02804338T patent/DK1450782T3/da active
- 2002-12-04 AT AT02804338T patent/ATE309800T1/de active
- 2002-12-04 JP JP2003548819A patent/JP4370169B2/ja not_active Expired - Fee Related
- 2002-12-04 PL PL371131A patent/PL211211B1/pl unknown
-
2007
- 2007-01-05 US US11/649,796 patent/US20070117762A1/en not_active Abandoned
-
2011
- 2011-10-25 US US13/280,749 patent/US8343979B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999003364A1 (en) * | 1997-07-16 | 1999-01-28 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Nutritional composition for subjects under stress |
WO2001026666A2 (en) * | 1999-10-08 | 2001-04-19 | Sigma-Tau Healthscience S.P.A. | Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba |
Non-Patent Citations (1)
Title |
---|
Acta Urol Ital., 10(3), 186-187, 1996 |
Also Published As
Publication number | Publication date |
---|---|
ES2250749T3 (es) | 2006-04-16 |
DK1450782T3 (da) | 2006-02-20 |
AU2002365847A1 (en) | 2003-06-17 |
DE60207442T2 (de) | 2006-07-27 |
US20120041005A1 (en) | 2012-02-16 |
US8343979B2 (en) | 2013-01-01 |
PL211211B1 (pl) | 2012-04-30 |
CA2465471C (en) | 2010-10-19 |
HUP0402062A3 (en) | 2012-09-28 |
EP1450782B1 (en) | 2005-11-16 |
ATE309800T1 (de) | 2005-12-15 |
JP4370169B2 (ja) | 2009-11-25 |
KR20050044594A (ko) | 2005-05-12 |
US20070117762A1 (en) | 2007-05-24 |
PL371131A1 (en) | 2005-06-13 |
JP2005511655A (ja) | 2005-04-28 |
EP1450782B9 (en) | 2006-05-17 |
US20050080018A1 (en) | 2005-04-14 |
ITRM20010708A0 (it) | 2001-12-04 |
EP1450782A1 (en) | 2004-09-01 |
ITRM20010708A1 (it) | 2003-06-04 |
HU229214B1 (hu) | 2013-09-30 |
SI1450782T1 (sl) | 2006-02-28 |
DE60207442D1 (de) | 2005-12-22 |
MXPA04005269A (es) | 2004-10-11 |
WO2003047563A1 (en) | 2003-06-12 |
CA2465471A1 (en) | 2003-06-12 |
HUP0402062A2 (hu) | 2005-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5690261B2 (ja) | β−ヒドロキシ−β−メチル酪酸および少なくとも1つのアミノ酸を含む組成物および使用法 | |
US8343979B2 (en) | Use of alkanoyl L-carnitine for the treatment of erectile dysfunction | |
CA1323572C (en) | Doxazosin as an anti-atherosclerosis agent | |
JPWO2004019928A1 (ja) | 肝疾患治療剤 | |
KR100244092B1 (ko) | L-카르니틴 또는 아실l-카르니틴과 ace-억제제를 함유한 심장혈관질환치료용 약제조성물과 그 치료방법 | |
JPH0337525B2 (ko) | ||
KR20120089623A (ko) | 정맥내 투여용 이부프로펜을 이용한 환자의 치료 | |
TWI513462B (zh) | 糖尿病之治療或預防藥 | |
US20040037896A1 (en) | Therapeutic treatment | |
KR101455275B1 (ko) | 발기 부전의 치료를 위한 아세틸 엘 카르니틴과 프로피오닐엘 카르니틴 및 실데나필과의 병용된 용도 | |
US20070087975A1 (en) | Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients | |
JPH02262519A (ja) | 糖尿病性神経障害治療剤 | |
JP5230195B2 (ja) | 心血管疾患の治療のためのl−カルニチンおよびグルコースの使用 | |
JP2004505919A (ja) | 一次性頭痛の処置におけるビタミン配合物の使用 | |
US4701467A (en) | Tolrestat as anti-hypertensive agent | |
JPS5920221A (ja) | レイノ−症状の改善・治療剤 | |
Beck et al. | Treatment of angina pectoris with isosorbide-5-mononitrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130625 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140625 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150624 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160627 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20170628 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20180627 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20190627 Year of fee payment: 11 |